Acute Myeloid Leukemia (AML)AMLSG BiONCT01252485
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
An observational study of Acute Myeloid Leukemia (AML) and MDS/AML, run by University of Ulm at 94 sites in 2 countries.
Trial summary
This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms Investigator's sites: 80-90 sites in Germany and Austria Estimated duration of observation of an individual patient: 10 years maximum Objectives To register all patients with AML and related neoplasms, newly… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myeloid Leukemia (AML), MDS/AML
- How many people
- 50,000 participants
- Where
- 94 sitesin 2 countries
- Study dates
- 6 Jul 2010to 31 Dec 2044
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with newly diagnosed or relapsed/refractory AML in all AMLSG participating centers (80-90 centers in Germany and Austria)
Who may be able to join
- Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification
- Age ≥ 18 years. There is no upper age limit.
- Signed written informed consent
Who cannot join
- Severe neurological or psychiatric disorder interfering with ability to give an informed consent
- No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation
- No consent for biobanking of patient's biological specimens and performance of analyses on stored material.
Trial locations and contacts
94 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
94 sites in 2 countries
Germany86 sites, 79 recruiting
- Recruiting
Klinikum Aschaffenburg
Aschaffenburg, 63739
Manfred Welslau, Dr.
- Suspended
Klinikum Augsburg
Augsburg, 86156
- Suspended
Ubbo-Emmius-Klinik Aurich
Aurich, 26603
- Recruiting
Helios Klinikum Bad Saarow
Bad Saarow, 15526
Daniel Schöndube, Dr.med.
- Recruiting
Vivantes Klinikum am Urban
Berlin, 10967
Annette Dieing, Dr.
- Recruiting
Vivantes Netzwerk für Gesundheit GmbH Klinikum Neukölln
Berlin, 12351
Maike De Wit, Prof. Dr. med.
- Recruiting
Charité Universitätsmedizin Berlin Campus Virchow Klinikum
Berlin, 13353
Jörg Westermann, PD Dr.
- Recruiting
Helios Klinikum Emil von Behring
Berlin
Immanuel Merz
- Recruiting
Vivantes Klinikum Spandau
Berlin
Joerg-Christian Rath, Dr.
- Recruiting
Augusta-Kranken-Anstalt
Bochum, 44791
Stefan Lukic, Dr.
- Recruiting
Medizinische Universitätsklinik Knappschaftskrankenhaus Bochum
Bochum, 44892
Roland Schroers, Prof. Dr.
- Recruiting
Universitätsklinikum Bonn
Bonn, 53105
Lino Teichmann, Dr.
- Recruiting
Städtisches Klinikum Braunschweig
Braunschweig, 38114
Jürgen Krauter, Prof. Dr.
- Recruiting
Klinikum Bremen-Mitte gGmbH
Bremen, 28177
Maher Hanoun, Prof. Dr. med.
- Recruiting
Klinikum Darmstadt
Darmstadt, 64283
Helga Bernhard, Prof. Dr. med.
- Recruiting
St. Johannes Hospital
Dortmund, 44137
Darina Kodzahbasheva, Dr.
- Recruiting
Universitätsklinikum Düsseldorf
Düsseldorf, 40225
Ulrich Germing, Prof.
- Recruiting
Marien Hospital Düsseldorf GmbH
Düsseldorf
Stefanie Groepper, Dr.
- Recruiting
Kliniken Essen-Süd Evang. Krankenhaus Essen-Werden gGmbH
Essen, 45239
Peter Reimer, Prof. Dr.
- Recruiting
Klinikum Esslingen GmbH
Esslingen am Neckar, 73730
Swen Wessendorf, PD Dr.
- Recruiting
St. Franziskus Hospital
Flensburg, 24939
Nicolai Faber, dr
- Recruiting
Städtische Kliniken Frankfurt am Main-Höchst
Frankfurt, 65929
Felicitas Scholten, Dr. med.
- Recruiting
Medizinische Universitätsklinik
Freiburg im Breisgau, 79106
Michael Lübbert, Prof. Dr.
- Suspended
MVZ Osthessen Medizinisches Versorgungszentrum
Fulda, 36043
- Recruiting
Klinik der Justus-Liebig-Universität
Giessen, 35385
Maisun Abu Samra, Dr.
- Recruiting
Wilhelm-Anton-Hospital gGmbH
Goch, 47574
Volker Runde, Prof. Dr. med.
- Recruiting
Alb Fils Kliniken GmbH
Göppingen, 73035
Martin Bommer, PD Dr.
- Recruiting
Universitätsmedizin Göttingen
Göttingen, 37075
Gerald Wulf, Prof. Dr.
- Recruiting
Universitätsmedizin Greifswald
Greifswald
Adrian Schwarzer, Prof.
- Recruiting
Universitätsklinikum Hall
Halle
Michael Heuser
- Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246
Franziska Westendorf, Dr.
- Recruiting
Asklepios Klinik Altona
Hamburg, 22763
Hans Salwender, Dr.
- Recruiting
Asklepios Kliniken Hamburg GmbH St. Georg
Hamburg
Ahmet Elmaagacli, Prof.
- Recruiting
Evangelisches Krankenhaus Hamm
Hamm, 59063
Alexander Baraniskin, Dr.
- Recruiting
Klinikum Hanau gGmbH
Hanau, 63450
Huesameddin Yildirim, Dr.
- Recruiting
Klinikum Hannover Siloah
Hanover, 30449
Kim Marienhagen, Dr.
- Recruiting
Medizinische Hochschule Hannover
Hanover, 30625
Felicitas Thol, PD Dr.
- Recruiting
SLK-Kliniken Heilbronn GmbH
Heilbronn, 74078
Uwe Martens, Prof. Dr.
- Recruiting
Marienhospital Herne Klinikum der Ruhr-Universität Bochum
Herne, 44625
Dirk Strumberg, Prof. Dr.
- Recruiting
Universitätsklinikum des Saarlandes
Homburg/Saar, 66424
Joerg Bittingbring, Dr.
- Recruiting
Westpfalz-Klinikum Kaiserslautern
Kaiserslautern, 67655
Gerhard Held, Prof.
- Recruiting
Städtisches Klinikum Karlsruhe
Karlsruhe, 76133
Martin Bentz, Prof. Dr.
- Recruiting
St. Vincentius-Kliniken Karlsruhe
Karlsruhe, 76137
Martina Gnadler
- Active, not recruiting
Klinikum Kassel GmbH
Kassel, 34125
- Suspended
Städtisches Krankenhaus Kiel GmbH
Kiel, 24116
- Recruiting
Helios Klinikum Krefeld
Krefeld
Ali Nuri Hünerlitürkoglu, Dr.
- Recruiting
Klinikum Landshut gGmbH
Landshut, 84034
Christian Bogner, Dr.
- Recruiting
Caritas Krankenhaus Lebach
Lebach, 66822
Stephan Kremers, Dr. med.
- Recruiting
Klinikum Lippe-Lemgo
Lemgo, 32657
Frank Hartmann, Prof. Dr. med.
- Recruiting
Universitätslinikum Schleswig-Holstein, Lübeck
Lübeck, 23538
Friederike Wortmann, Dr.
- Recruiting
Klinikum Lüdenscheid
Lüdenscheid, 58515
Monika Schwalenberg, Dr.
- Recruiting
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, 67063
Martin Hoffmann, Dr.
- Recruiting
Univ-Klinikum der Otto-von-Guericke-Universität
Magdeburg, 39120
Ana Maria Waldleben
- Recruiting
Klinikum Magdeburg gGmbH
Magdeburg, 39130
Christian Plate, Dr.
- Recruiting
Universitätsklinikum der Johannes Gutenberg-Universität Mainz
Mainz, 55131
Michael Kuehn, Dr.
- Recruiting
Klinikum Hochsauerland GmbH
Meschede, 59872
Mohammad Wattad, Dr.
- Recruiting
Johannes Wesling Klinikum Minden
Minden, 32429
Kai Wille, Dr.
- Recruiting
Evangelisches Krankenhaus Mülheim an der Ruhr GmbH
Mühlheim, 45466
Jan Schröder, Dr.
- Suspended
Klinikum Schwabing
München, 80804
- Recruiting
Klinikum rechts der Isar der TU München
München, 81675
Katharina Götze, Prof. Dr.
- Recruiting
Klinikum Schwäbisch-Gmünd
Mutlangen, 73557
Holger Hebart, Prof. Dr. med.
- Suspended
Städtische Kliniken Neuss Lukaskrankenhaus GmbH
Neuss, 41464
- Recruiting
Sana Klinikum Offenbach
Offenbach, 63069
Alexander Burchardt
- Recruiting
Ortenau Klinikum, Offenburg-Gengenbach
Offenburg, 77654
Irmgard Dresel, Dr.
- Recruiting
Pius Hospital Oldenburg
Oldenburg, 26121
Frank Griesinger, Prof. Dr.
- Recruiting
Klinikum Oldenburg gGmbH
Oldenburg, 26133
Andreas Voss, Dr.
- Recruiting
Klinikum Passau
Passau, 94032
Thomas Südhoff, Prof. Dr.
- Recruiting
Ernst-von-Bergmann-Klinikum Potsdam gGmbH
Potsdam, 14467
Su Hyeon Kim, Dr.
- Recruiting
Klinikum Vest
Recklinghausen, 45657
Michael Klein, Dr.
- Recruiting
Universitätsklinikum
Regensburg, 93053
Hendrik Poeck, Prof. Dr.
- Recruiting
University hospital Rostock
Rostock
Christian Junghanss
- Recruiting
Akademisches Lehrkrankenhaus des Saarlandes St. Theresia
Saarbrücken, 66113
Julian Alexis Topaly
- Recruiting
Marienhaus Klinikum St. Elisaeth Saarlouis
Saarlouis
Katharina Graeber, Dr.
- Recruiting
Nordwest-Krankenhaus Sanderbusch
Sande
Detlev Kohl, Dr
- Recruiting
Klinikum Stuttgart Katharinenhospital
Stuttgart, 70174
Jan Schleicher, Dr. med.
- Recruiting
Diakonie-Klinikum Stuttgart
Stuttgart, 70176
Jochen Greiner, Prof. Dr.
- Recruiting
Vinzenz von Paul Kliniken gGmbH Marienhospital Stuttgart
Stuttgart, 70199
Christian Jehn, Prof. Dr.
- Recruiting
Klinikum Traunstein
Traunstein, 83278
Thomas Kubin, Dr. med.
- Recruiting
Klinikum Mutterhaus der Borromäerinnen gGmbH
Trier, 54290
Tobias Buss, Dr. med.
- Recruiting
Krankenhaus der Barmherzigen Brüder Trier
Trier, 54292
Iordanis Deligiannis, Dr.
- Recruiting
Medizinische Universitätsklinik Tübingen
Tübingen, 72076
Claudia Lengerke, Prof.
- Recruiting
University Hospital of Ulm
Ulm, 89081
Hartmut Döhner, Prof. Dr., 49-731-500-45501, hartmut.doehner@uniklinik-ulm.de
- Recruiting
Universitätsklinik Ulm Labor für Zytogenetische und Molekulare Diagnostik
Ulm, 89081
Konstanze Döhner, Prof. Dr.
- Recruiting
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Villingen-Schwenningen, 78052
Paul Graf La Rosee, Prof. Dr.
- Recruiting
Harzklinikum Dorothea Christiane Erxleben
Wernigerode, 38855
Heiko Hütten
- Recruiting
Helios Klinikum Wuppertal
Wuppertal, 42283
Silke Schostok, Dr.
Austria8 sites, 7 recruiting
- Recruiting
Medizinische Universität Graz
Graz, 8036
Armin Zebisch, Prof. Dr.
- Recruiting
Medizinische Universität Innsbruck
Innsbruck, 6020
David Nachbaur, Prof. Dr.
- Suspended
Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.
Linz, 4010
- Recruiting
Krankenhaus der Elisabethinen Linz GmbH
Linz, 4020
Michael Girschikofsky, Dr.
- Recruiting
Kepler Universitätsklinikum GmbH
Linz
Clemens Schmitt, Prof.
- Recruiting
Landeskrankenhaus Feldkirch
Rankweil, 6807
Bernd Hartmann, Dr.
- Recruiting
Universitätsklinikum der PMU Landeskrankenhaus Salzburg
Salzburg
Lisa Pleyer
- Recruiting
Hanuschkrankenhaus Wien
Vienna, 1140
Elisabeth Koller, Dr.
About this study
This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms
Investigator's sites: 80-90 sites in Germany and Austria
Read more
Estimated duration of observation of an individual patient:
10 years maximum
Objectives
- To register all patients with AML and related neoplasms, newly diagnosed or relapsed/refractory in all AMLSG participating centers (completeness)
- To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations)
- To assess patient and family history, as well as patient characteristics
- To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival [EFS], relapse-free survival [RFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
- To evaluate the impact of measurable residual disease (MRD) by different methods
- To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
- To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue; e.g., skin biopsy, finger nails, hairs, sputum, or urine)
- Conditions
- Acute Myeloid Leukemia (AML), MDS/AML
- Keywords
- AML, Registry study, Biology and Outcome, MDS/AML
- Medical subject headings
- Leukemia, Myeloid, Acute
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of disease-related genetic markers
To perform rapid analyses of disease-related genetic markers (according to International Consensus Classification 2022) (incidences, treatment recommendations)
Measured: 4 weeks
Event-free survival
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Measured: 10 years
Cumulative incidence of relapse
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Measured: 10 years
Cumulative incidence of death
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Measured: 10 years
Overall survival
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Measured: 10 years
Treatment decision (intensive, non-intensive, investigational)
To perform rapid analyses of disease-related genetic markers (according to ICC 2022) (incidences, treatment recommendations)
Measured: 1 year
quality of life
Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, socioeconomics, and demographics according to Messerer D et al (2008), 6, 12 and 24 months after registration.
Measured: 2 years
Geographical representation
Geographical representation of patients through collection of patients zip codes
Measured: 1 day
Response to therapy
Rate of response: complete remission (CR), CR with partial hematologic recovery (CRh); CR with incomplete hematologic recovery (CRi)
Measured: 1 year
Relapse-free survival
Measured: 10 years
Measurable residual disease (MRD)
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2010 (estimated)
- Study start6 Jul 2010
- Primary completion31 Dec 2044 (estimated)
- Study completion31 Dec 2044 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid Leukemia (AML)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Ulm
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. Hartmut Doehner, University of Ulm
- Investigators
- Hartmut Döhner, Prof. Dr., Study chair, University Hospital of Ulm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01252485
- Sponsor's protocol ID
- AMLSG BiO
- Acronym
- AMLSG BiO
- Status last verified
- Dec 2025
- First submitted
- 2 Dec 2010
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
- ClinicalTrials.gov ID
- NCT01252485
- Acronym / sponsor ID
- AMLSG BiO / AMLSG BiO
- Conditions
- Acute Myeloid Leukemia (AML), MDS/AML
- Keywords
- AML, Registry study, Biology and Outcome, MDS/AML
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- University of UlmUniversity, hospital or other
- Study start
- 6 Jul 2010 (actual)
- Primary completion
- 31 Dec 2044 (estimated)
- Study completion
- 31 Dec 2044 (estimated)
- First posted
- 3 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms
Investigator's sites: 80-90 sites in Germany and Austria
Estimated duration of observation of an individual patient:
10 years maximum
Objectives
- To register all patients with AML and related neoplasms, newly diagnosed or relapsed/refractory in all AMLSG participating centers (completeness)
- To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations)
- To assess patient and family history, as well as patient characteristics
- To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival [EFS], relapse-free survival [RFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
- To evaluate the impact of measurable residual disease (MRD) by different methods
- To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
- To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue; e.g., skin biopsy, finger nails, hairs, sputum, or urine)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with newly diagnosed or relapsed/refractory AML in all AMLSG participating centers (80-90 centers in Germany and Austria)
Key inclusion criteria (3 listed)
- Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification
- Age ≥ 18 years. There is no upper age limit.
- Signed written informed consent
Key exclusion criteria (3 listed)
- Severe neurological or psychiatric disorder interfering with ability to give an informed consent
- No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation
- No consent for biobanking of patient's biological specimens and performance of analyses on stored material.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
incidence of disease-related genetic markers
Time frame: 4 weeks
To perform rapid analyses of disease-related genetic markers (according to International Consensus Classification 2022) (incidences, treatment recommendations)
Event-free survival
Time frame: 10 years
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Cumulative incidence of relapse
Time frame: 10 years
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Cumulative incidence of death
Time frame: 10 years
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Overall survival
Time frame: 10 years
To assess patient and family history, patient characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
Treatment decision (intensive, non-intensive, investigational)
Time frame: 1 year
To perform rapid analyses of disease-related genetic markers (according to ICC 2022) (incidences, treatment recommendations)
quality of life
Time frame: 2 years
Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, socioeconomics, and demographics according to Messerer D et al (2008), 6, 12 and 24 months after registration.
Geographical representation
Time frame: 1 day
Geographical representation of patients through collection of patients zip codes
Response to therapy
Time frame: 1 year
Rate of response: complete remission (CR), CR with partial hematologic recovery (CRh); CR with incomplete hematologic recovery (CRi)
Relapse-free survival
Time frame: 10 years
Measurable residual disease (MRD)
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
Related trials for Acute Myeloid Leukemia (AML)
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1/2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hartmut Döhner, Prof. Dr. study chair
University Hospital of Ulm
94 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myeloid Leukemia (AML) and MDS/AML, run by University of Ulm at 94 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 94 sites in Germany, Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hartmut Döhner, Prof. Dr. (49-731-500-45501, hartmut.doehner@uniklinik-ulm.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of disease-related genetic markers (time frame: 4 weeks). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.